Cue Biopharma stock falls after pricing capital raise of $20M via securities offering

Stock Information for Cue Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cue Biopharma Inc.

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
Cue Biopharma to Host Virtual Investor Event on May 15, 2025
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma to Host Business Update Call and Webcast
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.